A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Pembrolizumab (Primary) ; Bevacizumab; Cyclophosphamide
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Sep 2021 Status changed from active, no longer recruiting to completed.
- 23 Aug 2019 Planned End Date changed from 3 Aug 2020 to 3 Aug 2021.
- 23 Aug 2019 Planned primary completion date changed from 3 Aug 2019 to 3 Aug 2020.